Dietary
Supplements
The supplement industry operates under a unique framework unlike any other FDA-regulated category. No pre-market approval. No required clinical trials. But strict rules on what you can claim, how you manufacture, what ingredients you can use, and how you must label. This module covers the full DSHEA framework, the complete claims hierarchy with required disclaimer language, New Dietary Ingredient notifications, supplement GMP under 21 CFR Part 111, the Supplement Facts panel format, FTC dual jurisdiction over advertising, and the most common compliance failures that lead to enforcement action.
The DSHEA Framework — Understanding the Bargain
The Dietary Supplement Health and Education Act of 1994 (DSHEA) represents a deliberate policy choice by Congress: give the supplement industry freedom from pre-market approval in exchange for strict controls on what companies can claim about their products. Understanding this bargain is essential to advising supplement clients — they get to market without FDA approval, but they accept responsibility for safety and get very limited claim latitude.
Freedom Without Approval — But Not Without Rules
Under DSHEA, a dietary supplement manufacturer can put a product on the U.S. market without asking FDA's permission first — as long as the product contains a dietary ingredient, is labeled as a supplement, is not marketed as a conventional food, and makes only permissible claims. In exchange for this freedom, FDA must prove the product is unsafe to remove it from the market — the burden of proof is reversed compared to drugs. This explains why some clearly ineffective supplements remain on the market for years before FDA acts: the agency must demonstrate danger, not the manufacturer demonstrate safety before sale.
What Makes Something a Dietary Supplement
Under 21 U.S.C. § 321(ff), a dietary supplement must:
- Be intended to supplement the diet — not to replace a meal or be used as a conventional food
- Contain a dietary ingredient — vitamin, mineral, herb, botanical, amino acid, dietary substance to supplement the diet by increasing total dietary intake, or a concentrate, metabolite, constituent, extract, or combination thereof
- Be labeled as a dietary supplement — must bear the words "dietary supplement" or equivalent on the label
- Not be represented as a conventional food or meal — products marketed as meal replacements or conventional foods cannot simultaneously claim supplement status
- Be intended for ingestion — in tablet, capsule, softgel, gelcap, powder, liquid, or bar form (if bars, the label must clarify it is a supplement)
The Drug Exclusion Rule: Under 21 U.S.C. § 331(ll), a substance cannot be marketed as a dietary supplement if it has been approved as a drug or authorized for investigation as a new drug before being marketed as a supplement. This is why CBD (the active ingredient in FDA-approved Epidiolex) cannot legally be marketed as a dietary supplement — it was first approved as a drug. The same rule has been applied to other compounds that entered drug trials before supplement marketing began.
The Claims Hierarchy — The Most Critical Supplement Concept
The single most important compliance issue for any dietary supplement is claims. Every word on the label, website, social media post, Amazon listing, and marketing material is evaluated by FDA and FTC against the same standard: does this claim cross from permissible supplement territory into illegal drug territory? Getting this wrong converts your product into an unapproved new drug on every platform it appears.
Examples: "Treats Type 2 Diabetes" · "Cures arthritis" · "Prevents Alzheimer's disease" · "Reduces blood pressure in hypertension patients" · "For the treatment of depression" · "Clinically proven to fight cancer cells" · "Eliminates ADHD symptoms" · "Helps with COVID-19"
Authorized examples: "Adequate calcium and vitamin D throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis" · "Diets low in saturated fat and cholesterol may reduce the risk of heart disease" · "Folate may reduce the risk of neural tube birth defects"
Qualified health claims: Require specific FDA-mandated disclaimer language because scientific evidence is not conclusive. Example: "Selenium may reduce the risk of certain cancers. FDA has determined that this evidence is limited and not conclusive."
Examples: "Supports immune health" · "Promotes cardiovascular function" · "Helps maintain healthy cholesterol levels already within the normal range" · "Supports joint flexibility and mobility" · "Contributes to healthy energy metabolism" · "Helps maintain healthy blood sugar levels already within the normal range" · "Supports a healthy inflammatory response"
The "already within normal range" qualifier: This phrasing is critical — it distinguishes a structure/function claim ("maintains healthy blood sugar levels already within normal range") from a disease claim ("lowers blood sugar in diabetics"). The qualifier signals you're talking about healthy people maintaining health, not treating a condition.
Examples: "High in Vitamin C" · "Excellent source of calcium" · "Contains 1000mg Omega-3 fatty acids per serving" · "With zinc and selenium" · "100% daily value of Vitamin D"
The Required Disclaimer — Exact Wording Matters
Every structure/function claim on a supplement label must be accompanied by the exact disclaimer specified in 21 CFR § 101.93. The wording is prescribed by regulation — paraphrasing is not acceptable.
"Implied Disease Claims" — The Subtler Trap: FDA recognizes that companies sometimes try to make disease claims through indirect language. Implied disease claims are treated identically to explicit disease claims. Examples: "For prostate health" (implies treatment of prostate disease); "Heart formula" (implies treatment of heart disease); "Liver support for drinkers" (implies treatment of alcohol-related liver damage); showing a picture of someone at a doctor's office; using medical imagery alongside supplement claims. Any context that creates an implication of disease treatment = drug claim.
New Dietary Ingredient (NDI) Notifications
If a supplement contains a dietary ingredient that was not marketed in the U.S. before October 15, 1994, it is a "new dietary ingredient" (NDI) and requires a pre-market notification to FDA at least 75 days before the supplement is introduced into interstate commerce. This is one of the most frequently violated requirements in the supplement industry — manufacturers commonly use novel botanical extracts, isolated compounds, or synthetic nutrients without realizing they need to notify FDA first.
What an NDI Notification Must Include
- Identity of the new dietary ingredient (botanical name, chemical name, CAS number, specifications)
- The conditions of use — dose, dosage form, intended population
- Basis for concluding the ingredient will be reasonably expected to be safe — either history of use or other evidence of safety
- Complete bibliographic reference for all safety evidence submitted
- Statement of the specific dietary supplement in which the NDI will be used
If an NDI objection letter arrives: FDA's NDI objection letter does not prohibit marketing — it states that FDA does not consider the notification adequate. The manufacturer must then decide: (1) revise the notification with additional safety data, (2) reformulate using a grandfathered ingredient, or (3) accept the regulatory risk and market anyway (not recommended). FDA tracks objection letters and they become publicly available — a competitor or journalist can identify products that received objection letters.
Facility Registration and Listing for Supplements
Dietary supplement facilities are regulated as food facilities — they register through the same FURLS system used for conventional food, and they must comply with FSMA's food facility registration requirements. This means the registration rules from Module 05 apply directly to supplement manufacturers.
Supplement GMP — 21 CFR Part 111
Current Good Manufacturing Practice for dietary supplements is governed by 21 CFR Part 111. These regulations are distinct from drug GMP (21 CFR Part 211) and food cGMP (21 CFR Part 117), though they share conceptual similarities. Part 111 GMP applies to all supplement manufacturers, packagers, labelers, and holders — whether or not they're registered as food facilities.
The Identity Testing Requirement — Most Common GMP Failure: Under 21 CFR § 111.75, before using any component in a supplement, manufacturers must verify its identity through appropriate laboratory testing. You cannot rely solely on a certificate of analysis from the supplier — you must conduct identity testing yourself (or through a third party). This requirement is violated by a very high proportion of small supplement manufacturers and is one of the first things FDA inspectors look for. Every single ingredient, every single lot, must be identity-tested before use in production.
The Supplement Facts Panel — Format Requirements
The Supplement Facts panel is the dietary supplement equivalent of the Nutrition Facts panel — required on all dietary supplement labels under 21 CFR § 101.36. The format is precise and non-negotiable. Here is how a compliant Supplement Facts panel is structured:
† Daily Value not established for this nutrient.
Key Supplement Facts Panel Rules
- Panel header: "Supplement Facts" — mandatory header, in bold, at top of panel
- Serving size: Common household measure (capsules, tablets, teaspoons) + metric equivalent
- All dietary ingredients listed: In order shown — vitamins/minerals first, then botanicals/other ingredients
- Botanical identification: For herbs, must include: common name + Latin binomial (genus and species) + plant part used (root, leaf, aerial parts, fruit, seed, bark)
- % Daily Value: Listed for nutrients with established DVs; "†" with footnote for those without established DVs
- Chemical form: The specific chemical form used (e.g., "Vitamin C (as Ascorbic Acid)") — recommended and increasingly expected
- Other ingredients: Non-dietary ingredients (capsule shell, fillers, lubricants, anti-caking agents) listed after the Supplement Facts panel as "Other Ingredients" in descending order by weight
Complete Supplement Label Requirements
| Label Element | Requirement | Common Error |
|---|---|---|
| Statement of Identity | Must include "Dietary Supplement" or equivalent (e.g., "Herbal Supplement," "Vitamin Supplement") on PDP. Product name can also be included but "dietary supplement" descriptor is mandatory. | Omitting "dietary supplement" from the PDP; using "natural product" instead which doesn't satisfy the requirement |
| Net Quantity | Net quantity of contents by count (number of tablets/capsules), weight, or volume. Both U.S. and metric units. In bottom 30% of PDP. | Showing tablet count only without weight; metric-only label without U.S. equivalent |
| Manufacturer Name & Address | Name and place of business of manufacturer, packer, or distributor. "Distributed by" or "Manufactured for" phrases required if not the manufacturer. | P.O. box without physical address; missing country for foreign manufacturers |
| Supplement Facts Panel | Mandatory format per 21 CFR § 101.36. Serving size, servings per container, all dietary ingredients with amounts and % DV, other ingredients. | Missing botanical Latin names, wrong plant part specified, missing "†" for nutrients without established DV |
| Directions for Use | Required if product would be harmful without specific directions, or if directions are necessary for adequate use. For most supplements: serving size directions required ("Take 2 capsules daily with food"). | No directions at all; directions that don't match the serving size on the Supplement Facts panel |
| Structure/Function Disclaimer | Required on the label whenever any structure/function claim appears. Exact wording required per 21 CFR § 101.93. Must be in a box or similar enclosure, prominently displayed. | Disclaimer present but in fine print; disclaimer missing box/enclosure requirement; paraphrased disclaimer instead of exact wording |
| English Language | All required label information in English. Additional languages permitted but cannot replace English. Foreign-language-only labels = misbranded. | Bilingual labels where the English text is smaller or less prominent than the foreign language text |
| No "FDA Approved" Claims | Supplements are never FDA approved. Using "FDA Approved" or "FDA Certified" = misbranding. "Manufactured in an FDA-registered facility" is acceptable. | Misuse of FDA logo or language implying FDA endorsement |
FTC Dual Jurisdiction — The Advertising Regulator
Supplement companies face dual regulatory oversight: FDA regulates product labeling and safety, while the Federal Trade Commission (FTC) regulates advertising. Understanding the boundary between FDA jurisdiction (labeling) and FTC jurisdiction (advertising) is essential — and the distinction matters because the standards are similar but not identical.
- Product labels — all text on physical label and carton
- Labeling — any written/printed/graphic material accompanying the product
- Website — company website that promotes specific products
- Social media — company-controlled accounts
- Amazon / marketplace listings — product descriptions under company control
- Package inserts — any materials included in packaging
- Structure/function claim notifications — required within 30 days of first marketing
- All advertising — print, radio, TV, billboard, podcast sponsorships
- Online advertising — paid search, banner ads, sponsored social posts
- Influencer marketing — paid endorsements and partnerships
- Infomercials and direct response marketing
- Email marketing campaigns
- Endorsements and testimonials — both paid and unpaid if amplified
- Claim substantiation — FTC requires "competent and reliable scientific evidence" for all efficacy claims
The FTC's Substantiation Standard for Supplements
FTC requires that all efficacy and safety claims in supplement advertising be substantiated by "competent and reliable scientific evidence" before the claims are made. For health-related claims, FTC typically requires randomized, double-blind, placebo-controlled human clinical trials — the same standard FDA requires for drugs. Structure/function claims that FDA permits on labels with a disclaimer may still require clinical substantiation to satisfy FTC's advertising standards. This is a critical point many supplement companies miss: a claim that is legally permissible under FDA's DSHEA framework may still violate the FTC Act if not supported by adequate clinical evidence.
Influencer Marketing and the FTC: Under FTC's Endorsement Guides (updated 2023), any supplement brand paying an influencer — whether cash, free product, affiliate commission, or other compensation — must ensure that influencer clearly discloses the material connection in every post. The disclosure must be clear and conspicuous (not buried in hashtags). If an influencer makes efficacy claims for the supplement without substantiation, the brand can be held responsible. FTC has fined both brands and influencers in the supplement space.
Mandatory Adverse Event Reporting
Under the Dietary Supplement and Nonprescription Drug Consumer Protection Act (2006), supplement manufacturers must report serious adverse events to FDA. A serious adverse event is one that results in: death, a life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, congenital anomaly or birth defect, or medical or surgical intervention to prevent a serious outcome.
- 15 business days from receiving the report to filing with FDA
- Reported electronically via FDA's MedWatch system using Form 3500A
- Must include: product identification, adverse event description, consumer information, any medical attention sought
- Records of all adverse events (serious and non-serious) must be maintained for 6 years
- The label must include the domestic address or domestic phone number through which serious adverse events can be reported
Missing the Adverse Event Contact on the Label: Under 21 U.S.C. § 379aa-1, every dietary supplement label must bear a domestic address or domestic phone number for consumers to report serious adverse events. This is one of the most commonly missed labeling requirements — particularly for imported supplements from international manufacturers who don't think about U.S. contact requirements. Without this, the label is misbranded. The contact can be the U.S. distributor or US Agent.
Common Enforcement Triggers — What Gets Supplement Companies in Trouble
Traditional Medicine Product Meets U.S. Regulatory Reality
A Thai herbal supplement company has been selling a turmeric-ginger-black pepper capsule blend in Thailand and Southeast Asia for 8 years, marketed as "for joint health and mobility." They want to enter the U.S. market through Amazon. They contact Regovant for a compliance review. Here is what the review finds:
- Their Thai label: Claims "reduces inflammation and arthritis pain" — disease claims that convert the product to an unapproved drug in the U.S. Must be removed from all marketing materials before any U.S. sale.
- Proposed U.S. claims: "Supports healthy joint function and flexibility" with the required DSHEA disclaimer → permissible structure/function claims. 30-day FDA notification required before first marketing.
- NDI analysis: Turmeric (Curcuma longa), ginger (Zingiber officinale), and black pepper (Piper nigrum) — all marketed in the U.S. before October 15, 1994 as dietary ingredients. No NDI notification required for these specific botanicals in their current form. If they were to isolate piperine at a concentration not historically marketed, NDI notification may be required.
- Facility registration: Thai manufacturing facility must register with FDA as a food/dietary supplement facility. FEI number required. Biennial renewal. Regovant as US Agent.
- GMP assessment: Thai facility has ISO 22000 (food safety) certification but no 21 CFR Part 111 assessment. Need to verify identity testing program for incoming botanicals — this is the most likely GMP gap. Recommend a gap assessment against Part 111 before U.S. market entry.
- Label redesign: Supplement Facts panel required (currently has nutrition info in Thai format). Latin binomials for all botanicals required. Net weight must show ounces + grams. "Dietary Supplement" on PDP. US adverse event contact (Regovant address). Domestic phone number on label.
- Amazon-specific: Amazon's supplement compliance requirements (A-to-z Guarantee) require third-party testing certificates and CoA documentation. Arrange testing with a U.S.-accredited laboratory before listing.
- DSHEA (1994) is a bargain: no pre-market approval in exchange for strict claims control and reversed burden of proof. FDA must prove a supplement is unsafe to remove it — the manufacturer bears responsibility for safety but does not need FDA clearance before marketing.
- The claims hierarchy determines everything: nutritional content claims (always permitted), structure/function claims (permitted with disclaimer and 30-day notification), health claims (permitted only if FDA-authorized), disease claims (always illegal — convert the product to an unapproved new drug on every platform they appear).
- The required disclaimer under 21 CFR § 101.93 has exact prescribed wording: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Paraphrasing is not acceptable. Must appear in a box, prominently, near each structure/function claim.
- New Dietary Ingredient (NDI) notifications are required at least 75 days before marketing any supplement containing an ingredient not marketed in the U.S. before October 15, 1994. This requirement is frequently violated — check every ingredient in a client's formula against the pre-1994 grandfathered ingredient list before advising on market entry.
- Supplement GMP under 21 CFR Part 111 requires identity testing of every incoming ingredient before use. This is the most commonly violated GMP requirement and the first thing FDA inspectors look for. A Certificate of Analysis from the supplier is not sufficient — independent identity testing is required for each lot of each component.
- Every supplement label must include a domestic address or phone number for adverse event reporting. Missing this = automatic misbranding. The US Agent can serve as this contact — a practical service Regovant can provide to foreign supplement manufacturers alongside facility registration.
- FTC regulates supplement advertising with a "competent and reliable scientific evidence" standard that is effectively equivalent to drug clinical trial requirements for health claims. Structure/function claims permissible under FDA's DSHEA framework may still violate the FTC Act if not supported by randomized controlled human clinical trials. Influencer posts by paid partners are advertising subject to FTC's Endorsement Guides.
Need supplement compliance support for U.S. market entry?
Regovant provides supplement facility registration, claims review, NDI analysis, Supplement Facts panel review, and US Agent services for dietary supplement manufacturers entering the U.S. market.